Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients
- 1 April 1992
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (4) , 801-807
- https://doi.org/10.1128/aac.36.4.801
Abstract
A prospective randomized study was conducted to determine the efficacy of imipenem-cilastatin (hereafter referred to as imipenem) (500 mg four times daily) versus combination therapy for febrile neutropenic patients receiving either no prophylaxis or ciprofloxacin for prevention of infections. Combination therapy consisted of gentamicin (80 mg every 8 h) plus either cefuroxime (1,500 mg every 8 h) or cephalothin (1,000 mg every 4 h) for suspected catheter-related infections. Ninety-four neutropenic fever episodes in 87 patients were evaluable for efficacy. The overall clinical rate of response to imipenem was significantly higher than that to combination therapy (91 versus 74%; P = 0.05). The difference in efficacy was most pronounced in patients with microbiologically documented infections (89 versus 53%; P = 0.025), which were predominantly caused by gram-positive bacteria. Differences in susceptibility may have caused the better rate of response to imipenem. Two of 29 gram-positive bacteria were imipenem resistant, whereas 10 were resistant to cephalothin and cefuroxime and 12 were resistant to gentamicin. No causative gram-negative bacterium and 24 gram-positive bacteria were isolated in 61 fever episodes with ciprofloxacin prophylaxis (oral). In contrast, nine causative gram-negative and five gram-positive bacteria were isolated in 33 episodes without prophylaxis. The difference in distribution proved to be statistically significant for gram-negative (P = 0.0001) as well as gram-positive (P = 0.025) bacteria, indicating that ciprofloxacin effectively prevented the occurrence of gram-negative bacteria and may have contributed to the relatively large number of gram-positive bacteria isolated. Empirical initial therapy with imipenem may be a valuable alternative to combination therapy for neutropenic fever episodes.Keywords
This publication has 23 references indexed in Scilit:
- Failure of routine susceptibility tests to detect imipenem resistance among strains of methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1991
- From the Infectious Diseases Society of America: Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained FeverThe Journal of Infectious Diseases, 1990
- Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devicesAntimicrobial Agents and Chemotherapy, 1989
- Vancomycin, Ticarcillin, and Amikacin Compared with Ticarcillin-Clavulanate and Amikacin in the Empirical Treatment of Febrile, Neutropenic Children with CancerNew England Journal of Medicine, 1988
- High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemiaJournal of Molecular Medicine, 1987
- Imipenem/cilastatin therapy of infections in cancer patientsCancer, 1987
- A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and NeutropeniaNew England Journal of Medicine, 1986
- Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infectionsAntimicrobial Agents and Chemotherapy, 1986
- SEPTICAEMIA CAUSED BY VIRIDANS STREPTOCOCCI IN NEUTROPENIC PATIENTS WITH LEUKAEMIAThe Lancet, 1983
- Effects of the Combination of Gentamicin and Carbenicillin on the Bactericidal Activity of SerumThe Journal of Infectious Diseases, 1972